A Study of LY3405105 in Participants With Advanced Cancer

Inclusion Criteria

• •Phase 1 a:
• •Have histological or cytological evidence of a diagnosis of a solid tumor cancer that is advanced and/or metastatic
• •Have available archived tissue for exploratory biomarker analysis
• •Have adequate organ function
• •Have discontinued all previous treatments for cancer and recovered from their side effects
• •Are able to swallow capsules/tablets
• •Phase 1 b:
• •Cohort 1: Triple-negative breast cancer (TNBC).
• •Cohort 2: Clear cell ovarian cancer, endometrioid ovarian cancer, or endometrioid endometrial carcinoma with a LOF mutation in one or more of the following genes: ARID1A, KMT2C (MLL3), KMT2D (MLL2), or KDM6A (UTX).
• •Cohort 3: Soft tissue sarcoma or sarcomatoid/rhabdoid malignancy with loss of expression of INI1, BRG1, or BRM by immunohistochemistry or a LOF mutation in one or more of the following genes: ARID1A, SMARCA2, SMARCA4, or SMARCB1. Participants aged ≥ 12 years with a body weight of ≥ 40 kilogram (kg) are acceptable for Cohorts 3. Participants with synovial sarcoma and a confirmed SS18-SSX gene fusion are also eligible.
• •Cohort 4: Epithelioid sarcoma with INI1 loss of expression by immunohistochemistry or SMARCB1 LOF mutation. Participants aged ≥ 12 years with a body weight of ≥ 40 kilogram (kg) are acceptable for Cohorts 4.
• •Cohort 5: Bladder cancer with a LOF mutation in one or more of the following genes: ARID1A, KMT2C (MLL3), KMT2D (MLL2), or KDM6A (UTX).